Samsung Biologics, a global contract development and manufacturing organization (CDMO), has announced a series of manufacturing deals with a Europe-based pharmaceutical company.   The disclosed deals, worth over $668 million combined, will run through December 2031. The latest agreements bring up the company’s cumulative contract value for this year to more than $4 billion.   “We are delighted to expand our partnership with the European pharmaceutical company toward our shared co...